Azathioprine and anti-TNFα therapies in Crohn's disease: A review of pharmacology, clinical efficacy and safety

Pharmacological Research

Volumn 47, Issue 1, 2003, Pages 1-10

  Arnott, Ian D R ^a   Watts, David ^a   Satsangi, Jack ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Crohn's disease; Infliximab; Tumour necrosis factor

Indexed keywords

AZATHIOPRINE; ETANERCEPT; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; ONERCEPT; PENTOXIFYLLINE; SEMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ALLERGIC REACTION; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRONCHOSPASM; CANCER; CHRONIC DISEASE; CLINICAL TRIAL; CROHN DISEASE; DERMATITIS; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG DEGRADATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENTERITIS; ERYTHEMA; FETUS MALFORMATION; FEVER; HEADACHE; HEPATITIS; HUMAN; IMMUNOMODULATION; INFECTION; INFERTILITY; LEUKOPENIA; MALAISE; MORBIDITY; NAUSEA; PANCREATITIS; PERIPHERAL NEUROPATHY; PREGNANCY; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; STRIDOR; TREATMENT OUTCOME; URTICARIA;

6-MERCAPTOPURINE; ANIMALS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037282538     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00264-5     Document Type: Review

References (105)

1. Rubin G.P., Hungin A.P., Kelly P.J., Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment. Pharmacol. Ther. 14:2000;1553-1559.
2. Sawczenko A., Sandhu B.K., Logan R.F., Jenkins H., Taylor C.J., Mian S.et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet. 357:2001;1093-1094.
3. Armitage E., Drummond H., Ghosh S., Ferguson A. Incidence of juvenile-onset Crohn's disease in Scotland (letter). Lancet. 353:1999;1496-1497.
4. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J.et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:2001;599-603.
5. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R.et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 411:2001;603-606.
6. Cosnes J., Beaugerie L., Carbonnel F., Gendre J.P. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 120:2001;1093-1099.
7. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. Clin. Pharmacol. 43:1992;329-339.
8. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am. J. Gastroenterol. 91:1996;423-433.
9. VanOs E.C., Zins B.J., Sandborn W.J., Mays D.C., Tremaine W.J., Mahoney D.W.et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 39:1996;63-68.
10. Ewe K., Press A.G., Singe C.C., Stufler M., Ueberschaer B., Hommel G.et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 105:1993;367-372.
11. Candy S., Wright J., Gerber M., Adams G., Gerog M., Goodman R. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut. 37:1995;674-678.
12. Sandborn WJ, Pearson AD, May GR, Modgliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease (Cochrane review). The Cochrane Library; 2002.
13. Nielsen O.H., Vainer B., Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. 15:2002;1699-1708.
14. Sandborn W.J., Tremaine W.J., Wolf D.C., Targan S.R., Sninsky C.A., Sutherland L.R.et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 117:1999;527-535.
15. Pearson AD, May GR, Fick G, Sutherland LR. Azathioprine for maintenance of remission in Crohn's disease (Cochrane review). The Cochrane Library; 2002.
16. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30-year review. Gut. 50:2002;485-489.
17. O'Donoghue D.P., Dawson A.M., Powell-Tuck J., Bown R.L., Lennard-Jones J.E. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 2:1978;955-957.
18. Camma C., Giunta M., Rosselli M., Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 113:1997;1465-1473.
19. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann. Intern. Med. 123:1995;132-142.
20. Bouhnik Y., Lemann M., Mary J.Y., Scemama G., Tai R., Matuchansky C.et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 347:1996;215-219.
21. Present D.H., Korelitz B.I., Wisch N., Glass J.L., Sachar D.B. Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomised, double-blind study. N. Engl. J. Med. 302:1980;981-987.
22. Korelitz B., Hanauer S., Rutgeerts P., Present D., Peppercorn M. 5-ASA or placebo in Crohn's disease: a 2-year multicenter trial. Gastroenterology. 114:1998;G4141.
23. Cuillerier E., Lemann M., Bouhnik Y., Allez M., Rambaud J.C., Modigliani R. Azathioprine for prevention of post-operative recurrence in Crohn's disease: a retrospective study. Eur. J. Gastroenterol. Hepatol. 13:2001;1291-1296.
24. Connell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 34:1993;1081-1085.
25. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short-term and long-term toxicity. Ann. Intern. Med. 111:1989;641-649.
26. Gerhartz H.H., Stern A.C., Wolfhornung B., Kazempour M., Schmetzer H., Gugerli U.et al. Intervention treatment of established neurtopenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhgm-csf) in patients undergoing cancer chemotherapy. Leukemia Res. 17:1993;175-185.
27. Arnott I.D.R., Ghosh S. Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury. Eur. J. Gastroenterol. Hepatol. 12:2000;569-573.
28. Garnier J.L., Lebranchu Y., Dantal J., Bedrossian J., Cahen R., Assouline D.et al. Hodgkin's disease after transplantation. Transplantation. 61:1996;71-76.
29. Farrell R.J., Ang Y., Kileen P., O'Briain D.S., Kelleher D., Keeling P.W.N.et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 47:2000;514-519.
30. Connell W.R., Kamm M.A., Dickson M., Balkwill A.M., Ritchie J.K., Lennard-Jones J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 343:1994;1249-1252.
31. Fraser A.G., Jewell D.P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine: a 30-year study. Gastroenterology. 118:2000;1471.
32. Thomsen J.B., Schroder H., Kristinsson J., Madsen B., Szumlanski C., Weinshilboum R.et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer. 86:1999;1080-1086.
33. Relling M.V., Rubnitz J.E., Rivera G.K., Boyett J.M., Hancock M.L., Felix C.A.et al. High incidence of secondary brain tumours after radiotherapy and anti-metabolites. Lancet. 354:1999;34-39.
34. Lewis J.D., Schwartz J.S., Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 118:2000;1018-1024.
35. Lewis J.D., Bilker W.B., Brensinger C., Deren J.J., Vaughn D.J., Strom B.L. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 121:2002;1080-1087.
36. McGovern D.P., Travis S.P., Duley J., Shobowale-Bakre E.M., Dalton H.R. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology. 122:2002;838-839.
37. Dominitz J.A., Young J.C., Boyko E.J. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol. 97:2002;641-648.
38. Alstead E.M., Ritchie J.K., Lennard-Jones J.E., Farthing M.J.G., Clark M.L. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 99:1990;443-446.
39. Korelitz B.I. Inflammatory bowel disease and pregnancy. Gastroenterol. Clin. North Am. 27:1998;213-214.
40. Roubenoff R., Hoyt J., Petri M., Hochberg M.C., Hellmann D.B. Effects of anti-inflammatory and immunosuppressive drugs on pregnancy and fertility. Semin. Arthritis Rheum. 18:1988;88-110.
41. Ramsey-Goldman R., Schilling E. Immunosuppressive drug use during pregnancy. Rheum. Dis. Clin. North Am. 23:1997;149-167.
42. Rajapakse R.O., Korelitz B.I., Zlatanic J., Baiocco P.J., Gleim G.W. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am. J. Gastroenterol. 95:2000;684-688.
43. Kane S.V. What's good for the goose should be good for the gander-6-MP use in fathers with inflammatory bowel disease. Am. J. Gastroenterol. 95:2000;581-582.
44. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32:1980;651-662.
45. Lennard L., Vanloon J.A., Lilleyman J.S., Weinshilboum R.M. Thiopurine pharmacogenetics in leukaemia-correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 41:1987;18-25.
46. Lennard L., Lilleyman J.S., Vanloon J., Weinshilboum R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 336:1990;225-229.
47. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 51:2002;143-146.
48. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y.et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 118:2000;705-713.
49. Cuffari C., Theoret Y., Latour S., Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 39:1996;401-406.
50. Cuffari C., Hunt S., Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 48:2001;642-646.
51. Dubinsky M.C., Yang H.Y., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T.et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 122:1902;904-915.
52. Belaiche J., Desager J.P., Horsmans Y., Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand. J. Gastroenterol. 36:2001;71-76.
53. Sandborn W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 48:2001;591-592.
54. Schutz E., Gummert J., Armstrong V.W., Mohr F.W., Oellerich M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur. J. Clin. Chem. Clin. Biochem. 34:1996;199-205.
55. Krynetski E.Y., Schuetz J.D., Galpin A.J., Pui C.H., Relling M.V., Evans W.E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. U.S.A. 92:1995;949-953.
56. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., ParkHah J.O.et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62:1997;60-73.
57. Otterness D.M., Szumlanski C.L., Wood T.C., Weinshilboum R.M. Human thiopurine methyltransferase pharmacogenetics: kindred with a terminal exon splice junction mutation that results in loss of activity. J. Clin. Invest. 101:1998;1036-1044.
58. Szumlanski C., Otterness D., Her C., Lee D., Brandriff B., Kelsell D.et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15:1996;17-30.
59. Tai H.L., Krynetski E.Y., Yates C.R., Loennechen T., Fessing M.Y., Krynetskaia N.F.et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58:1996;694-702.
60. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H.et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126:1997;608.
61. Papadakis K.A., Targan S.R. Tumour necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 119:2000;1148-1157.
62. Sandborn W.J., Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology. 122:2002;1592-1608.
63. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F.et al. Maintenance Infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:2002;1541-1549.
64. Derkx B., Taminiau J., Radema S., Stronkhorst A., Wortel C., Tytgat G.et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet. 342:1993;173-174.
65. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N.et al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 109:1995;129-135.
66. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T.et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337:1997;1029-1035.
67. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A.et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340:1999;1398-1405.
68. Cohen R.D., Tsang J.F., Hanauer S.B. Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95:2000;3469-3477.
69. Farrell R.J., Shah S.A., Lodhavia P.J., Alsahli M., Falchuk K.R., Michetti P.et al. Clinical experience with Infliximab therapy in 100 patients with Crohn's disease. Am. J. Gastroenterol. 95:2000;3490-3497.
70. Ricart E., Panaccione R., Loftus E.V., Tremaine W.J., Sandborn W.J. Infliximab for Crohn's disease in clinical practice at the mayo clinic: the first 100 patients. Am. J. Gastroenterol. 96:2001;722-729.
71. Arnott I.D.R., McDonald D., Williams A., Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment. Pharmacol. Ther. 15:2001;1639-1646.
72. Cohen R.D. Efficacy and safety of repeated Infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm. Bowel Dis. 7:1902;S17-S22.
73. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H.et al. Efficacy and safety of re-treatment with anti-tumour necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology. 117:1999;761-769.
74. Lipsky P.E., van der Heijde D.M.F.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R.et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343:2000;1594-1602.
75. Sands B., van Deventer S., Bernstein C., Kamm M., Rachmilewitz D., Chey W.et al. Long-term treatment of fistulising Crohn's disease: response to Infliximab in the ACCENT II trial through 54 weeks. Gastroenterology. 122:1902;671.
76. Schreiber S., Campieri M., Colombel J.F., van Deventer S.J.H., Feagan B., Fedorak R.et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001-2003. Int. J. Colorectal Dis. 16:2001;1-11.
77. Hanauer S.B., Schaible T.F., DeWoody K.L., Marsters P.A., Peltier M., Dittrich K.et al. Long-term follow-up of patients treated with Infliximab (anti-TNFα antibody) in clinical trials. Gastroenterology. 118:2000;2961.
78. Kugathasan S., Levy M.B., Saeian K., Vasilopoulos S., Kim J.P., Prajapati D.et al. Infliximab re-treatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. 97:2002;1408-1414.
79. Farrell R.J., Alsahli M., Falchuk K.R., Peppercorn M.A., Michetti P. Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following Infliximab therapy. Gastroenterology. 120:1902;364.
80. Farrell R.J., Alsahli M., Falchuk K.R., Peppercorn M.A., Michetti P. A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following Infliximab therapy. Gastroenterology. 120:1902;3140.
81. Baker D.G., Clark J., Keenan G.F., Jones S. Tuberculosis occurring in patients receiving the anti-TNF agent Infliximab. Arthritis Rheum. 44:1902;317.
82. Aberra F.N., McGregor J., Brennan P.R., Lichtenstein G.R. Is a PPD skin test result sufficient in determining risk for reactivation of latent TB infection in IBD patients that are candidates for Infliximab therapy? Gastroenterology. 122:1902;W1362.
83. Remicade (Infliximab). Prescribing information. Physicians desk reference; 2001, p. 1085-8.
84. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D.et al. Tuberculosis associated with Infliximab, a tumour necrosis factor (alpha)-neutralizing agent. N. Engl. J. Med. 345:1902;1098-1104.
85. Warris A., Bjorneklett A., Gaustad P. Invasive pulmonary aspergillosis associated with Infliximab therapy. N. Engl. J. Med. 344:1902;1099-1100.
86. Arnott I.D.R., Ghosh S. Treatment of Crohn's disease with Infliximab does not reduce hospital attendance or admission. Gastroenterology. 122:1902;W1361.
87. Colombel J.F., Rutgeerts P., Yan S.K., Bala M., Bao W., Olson A.et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients. Gastroenterology. 122:1902;W1344.
88. van Heel D.A., Kinouchi Y., Cardon L.R., Lench N.J., Jewell D.P. Transmission disequilibrium testing confirms the association of the TNF alpha-1031C allele with Crohn's disease. Gut. 48:2001;319.
89. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Pescatore P.et al. A positive response to infliximab in Crohn disease: association with a higher systematic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37:2002;818-824.
90. Taylor K.D., Plevy S.E., Yang H.Y., Landers C.J., Barry M.J., Rotter J.I.et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 120:2001;1347-1355.
91. Esters N., Vermeire S., Joossens S., Noman M., Louis E., Belaiche J.et al. Serological markers for prediction of response to anti-tumour necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97:2002;1458-1462.
92. Mascheretti S., Hampe J., Croucher P.J.P., Kuhbacher T., Andus T., Herfarth H.et al. Lack of association between SNPS in the NOD2 gene and response to Infliximab treatment in Crohn's disease. Gastroenterology. 122:1902;W1338.
93. Vermeire S., Louis E., Rutgeerts P., De Vos M., Van Gossum A., Belaiche J.et al. NOD2/CARD15 does not influence response to Infliximab in Crohn's disease. Gastroenterology. 123:2002;106-111.
94. Stack W.A., Mann S.D., Roy A.J., Heath P., Sopwith M., Freeman J.et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor alpha in Crohn's disease. Lancet. 349:1997;521-524.
95. Sandborn W.J., Feagan B.G., Hanauer S.B., Present D.H., Sutherland L.R., Kamm M.A.et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 120:1902;1330-1338.
96. Sandborn W.J., Hanauer S.B. Anti-tumour necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5:1999;119-133.
97. D'Haens G., Swijsen C., Noman M., Lemmens L., Ceuppens J., Agbahiwe H.et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am. J. Gastroenterol. 96:2002;2564-2568.
98. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D.et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 121:2002;1088-1094.
99. Hommes D., Van Den Blink B., Plasse T., Bartelsman J., Xu C.P., MacPherson B.et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 122:2002;7-14.
100. Kenet G., Wardi J., Avni Y., Aeed H., Shirin H., Zaidel L.et al. Amelioration of experimental colitis by thalidomide. Israel Med. Assoc. J. 3:2002;644-648.
101. Bauditz J., Wedel S., Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 50:2002;196-200.
102. Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., Hassard P.V., Papadakis K.A., Yang H.Y.et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 117:1999;1278-1287.
103. Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., Hanauer S.B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 117:1999;1271-1277.
104. Sabate J.M., Villarejo J., Lemann M., Bonnet J., Allez M., Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to Infliximab in chronically active and fistulising refractory Crohn's disease. Aliment. Pharmacol. Ther. 16:2002;1117-1124.
105. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid-dependent chronic active Crohn's disease. Gut. 40:1997;470-474.